ReviewReviews in cardiovascular medicine2026
Obstructive Sleep Apnoea and Atrial Fibrillation: Current Evidence and Emerging Research Directions.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review summarizes current knowledge on the coexistence of obstructive sleep apnoea and atrial fibrillation. A narrative review of the literature was conducted to identify relevant clinical and mechanistic studies. Obstructive sleep apnoea is highly prevalent among patients with atrial fibrillation and adversely affects rhythm-control outcomes. The interplay between these two conditions is of significant clinical importance, as obstructive sleep apnoea contributes to the development and progression of arrhythmias through multiple pathophysiological mechanisms: mechanical atrial stretch, immune activation and low-grade inflammation, autonomic dysregulation, oxidative stress, and systemic hypoxia. These mechanisms promote the initiation, maintenance, and treatment resistance of atrial fibrillation. Multimodal management strategies aimed at this harmful interplay may improve outcomes in patients with atrial fibrillation and include lifestyle and dietary interventions, pharmacometabolic therapies, particularly glucagon-like peptide-1 receptor agonists, continuous positive airway pressure therapy, and, in selected cases, catheter ablation strategies, potentially extended to the ganglionated plexi. Collectively, these approaches may contribute to the restoration and maintenance of sinus rhythm.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.